(FM) Medicina Interna
Departamento académico
University Medical Center
Lubbock, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University Medical Center (2)
2024
-
Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Journal of Clinical Oncology, Vol. 42, Núm. 23, pp. 2790-2799
2023
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516